Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.77 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.77 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.77 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 2/20 | 0.77 |
| ▸ | WEE1 | P30291 | 5/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762370 | 0.88 | FGFR1 (0.64) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4839269 | 0.87 | FGFR1 (1.00) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5760862 | 0.84 | FGFR1 (0.55) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2245255 | 0.82 | FGFR1 (0.67) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4423133 | 0.82 | SRC (0.66) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26930657 | 0.79 | BRAF (0.64) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL31338489 | 0.79 | BRAF (0.64) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL16426416 | 0.78 | SIK2 (0.61) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5057413 | 0.77 | SRC (0.54) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL24224923 | 0.76 | FGFR1 (0.65) | SRCFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| US-5620981-A | ANTICARCINOGENIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS, PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
| US-5945422-A | ANTICANCER AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
| US-5733914-A | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| US-5620981-A | ANTICARCINOGENIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS, PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |